Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy
Open Access
- 24 June 2020
- journal article
- research article
- Published by Elsevier BV in Acta Pharmaceutica Sinica. B
- Vol. 11 (1), 156-180
- https://doi.org/10.1016/j.apsb.2020.06.003
Abstract
No abstract availableKeywords
Funding Information
- Department of Science and Technology of Sichuan Province (20YYJC3921, 81922064, 81673455, U1603123, 81573290, 81874290)
- National Natural Science Foundation of China (20YYJC3921, 81922064, 81673455, U1603123, 81573290, 81874290)
This publication has 74 references indexed in Scilit:
- Targeted Therapy for Breast Cancer PreventionFrontiers in Oncology, 2013
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain FamilyCell, 2012
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaNature, 2011
- Structures of the Dual Bromodomains of the P-TEFb-activating Protein Brd4 at Atomic ResolutionOnline Journal of Public Health Informatics, 2009
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation CarriersThe New England Journal of Medicine, 2009
- The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional RegulationJournal of Biological Chemistry, 2007
- Basal-like breast carcinomas: clinical outcome and response to chemotherapyJournal of Clinical Pathology, 2006
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005
- Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine KinaseCancer Research, 2004